N'-Ethyl-1-methyl-nipecotamid | 4138-14-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N'-Ethyl-1-methyl-nipecotamid
• 英文别名: 1-methyl-piperidine-3-carboxylic acid ethylamide；N-ethyl-1-methylpiperidine-3-carboxamide
• CAS: 4138-14-1
• 化学式: C₉H₁₈N₂O
• mdl: MFCD24392059
• 分子量: 170.255
• InChiKey: NTFQBHKWVCPAQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.888
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Bessis Anne-Sophie

  公开号：US20110112143A1

  公开（公告）日：2011-05-12

  The present invention relates to new compounds of formula (I) wherein A, B, P, Q, W, R 1 and R 2 are defined in the description; invention compounds are useful in the prevention or treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors.

  本发明涉及公式（I）的新化合物，其中A、B、P、Q、W、R1和R2在说明书中有定义；发明的化合物在预防或治疗中枢神经系统疾病以及其他被mGluR5受体调节的疾病方面是有用的。
• AZOLECARBOXAMIDE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP2009005A1

  公开（公告）日：2008-12-31

  Provided is an agent for treating or preventing urinary frequency, urinary urgency and urinary, incontinence which are associated with overactive bladder, a lower urinary tract disease such as interstitial cystitis and chronic prostatitis accompanied by lower urinary tract pain, and various diseases accompanied by pain. A novel azolecarboxamide derivative in which an azole ring such as thioazole or oxazole is bonded to a benzene ring, pyridine ring or pyrimidine ring through carboxamide was confirmed to have a potent trkA receptor-inhibitory activity and found to be an agent for treating or preventing lower urinary tract disease and various diseases accompanied by pain, which is excellent in efficacy and safety, and thus the present invention was accomplished.

  本发明提供了一种用于治疗或预防尿频、尿急和尿失禁的药物，这些症状与膀胱过度活动症、伴有下尿路疼痛的下尿路疾病（如间质性膀胱炎和慢性前列腺炎）以及伴有疼痛的各种疾病有关。一种新型唑甲酰胺衍生物，其中硫氮唑或噁唑等唑环通过羧酰胺键合到苯环、吡啶环或嘧啶环上，被证实具有强效的 trkA 受体抑制活性，并被发现是一种治疗或预防下尿路疾病和伴有疼痛的各种疾病的药物，其疗效和安全性都很好，从而完成了本发明。
• 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors
  申请人：Boehringer Ingelheim International GmbH

  公开号：US11001570B2

  公开（公告）日：2021-05-11

  The present invention encompasses compounds of formula (I), wherein the groups R1 to R5, X, Y and W have the meanings given in the claims and specification, their use as inhibitors of BCL6, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.

  本发明包括式（I）化合物（其中基团 R1 至 R5、X、Y 和 W 具有权利要求书和说明书中给出的含义）、其作为 BCL6 抑制剂的用途、含有此类化合物的药物组合物以及其作为药物的用途，特别是作为治疗和/或预防肿瘤疾病的药物。
• HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS
  申请人：Aventis Pharmaceuticals Inc.

  公开号：EP1632483B1

  公开（公告）日：2008-10-29
• PYRIMIDINE DERIVATIVES AS PROTEIN TYROSINE KINASE 2 INHIBITORS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2483249B1

  公开（公告）日：2015-12-23